drugset
drugset / Trial / NCT02532712

Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers

NCT02532712 ↗

Phase 1 Completed 64 enrolled Enzychem Lifesciences Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a Dose block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I clinical trial to assess the safety, tolerability and pharmacokinetics of single-dose and multiple-dose oral administration of the investigational product, EC-18 (study drug) in healthy adult male volunteers.

Timeline

Start
2015-03
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MOSEDIPIMOD Small molecule 500 mg Oral
Subject MOSEDIPIMOD Small molecule 1000 mg Oral
Subject MOSEDIPIMOD Small molecule 2000 mg Oral
Subject MOSEDIPIMOD Small molecule 4000 mg Oral

Indications

neutropenia